Pharmacology of α1-adrenoceptor antagonists in the lower urinary tract and central nervous system

Nature Clinical Practice Urology

Volumn 4, Issue 7, 2007, Pages 368-378

  Andersson, Karl Erik ^a,b   Gratzke, Christian ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N [2 (2 CYCLOPROPYLMETHOXYPHENOXY)ETHYL] ALPHA,ALPHA DIMETHYL 1H INDOLE 3 ETHANAMINE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; CHLORTALIDONE; DOXAZOSIN; FINASTERIDE; NAFTOPIDIL; PLACEBO; PRAZOSIN; SILODOSIN; TADALAFIL; TAMSULOSIN; TERAZOSIN; TRANSFORMING GROWTH FACTOR BETA1; VARDENAFIL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;

APOPTOSIS; BINDING AFFINITY; BLADDER; BLOOD PRESSURE REGULATION; CENTRAL NERVOUS SYSTEM; CHOLINERGIC NERVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; DETRUSOR DYSSYNERGIA; DIZZINESS; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION DISORDER; EPITHELIUM CELL; GANGLION; HUMAN; IRIS DISEASE; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; MUSCLE CONTRACTION; NERVE ENDING; NONHUMAN; ORGAN BLOOD FLOW; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; QUALITY OF LIFE; RECEPTOR BINDING; RECEPTOR BLOCKING; REVIEW; SEDATION; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; STROMA CELL; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URETHRA; UROLOGY; VAS DEFERENS; VASCULAR RESISTANCE; ANIMAL; CARDIOVASCULAR SYSTEM; DRUG EFFECT; EJACULATION; IRIS; MALE; UROGENITAL SYSTEM;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; EJACULATION; HUMANS; IRIS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; URETHRA; URINARY BLADDER; UROGENITAL SYSTEM; VAS DEFERENS;

EID: 34547764852     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0836     Document Type: Review

References (98)

1. Mitterberger M et al. (2007) Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU Int 99: 831-835
2. Andersson KE (2003) Storage and voiding symptoms: Pathophysiologic aspects. Urology 62 (Suppl 2): 3-10
3. Jardin A et al. (1998) Alpha-blockers in the treatment of BPH. In 4th International Consultation on Benign Prostatic Hyperplasia (BPH) 599-632 (Eds Denis L et al.). Plymouth: Health Publication Ltd
4. Rossi C et al. (2001) Alpha-blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J Urol 165: 38-41
5. Kessler TM et al. (2006) The effect of terazosin on functional bladder outlet obstruction in women: A pilot study. J Urol 176 1487-1492
6. Chapple CR and Roehrborn CG (2006) A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. Eur Urol 49: 651-688
7. Roehrborn CG and Schwinn DA (2004) Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 171: 1029-1035
8. Michel MC and Vrydag W (2006) Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147 (Suppl 2): S88-S119
9. Hampell C et al. (2002) Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 167: 1513-1521
10. Nomiya M and Yamaguchi O (2003) A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 170: 649-653
11. Bouchelouche K et al. (2005) Increased contractile response to phenylephrine in detrusor of patients with bladder outlet obstruction: effect of the alpha1A and alpha1D-adrenergic receptor antagonist tamsulosin. J Urol 173: 657-661
12. Ohtake A et al. (2006) Effect of tamsulosin on spontaneous bladder contraction in conscious rats with bladder outlet obstruction: comparison with effect on intraurethral pressure. Eur J Pharmacol 545: 185-191
13. Tatemichi S et al. (2006) A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 176: 1236-1241
14. Malloy BJ et al. (1998) Alpha1-adrenergic receptor subtypes in human detrusor. J Urol 160: 937-943
15. Berger AP et al. (2003) Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57: 57-65
16. Das AK et al. (2002) Effect of doxazosin on rat urinary bladder function after partial outlet obstruction. Neurourol Urodyn 21 160-166
17. Somogyi GT et al. (1995) Prejunctional facilitatory alpha 1-adrenoceptors in the rat urinary bladder. Br J Pharmacol 114 1710-1716
18. Szell EA et al. (2000) Smooth muscle and parasympathetic nerve terminals in the rat urinary bladder have different subtypes of alpha(1) adrenoceptors. Br J Pharmacol 130: 1685-1691
19. Trevisani M et al. (2007) The influence of alpha(1)-adrenoreceptors on neuropeptide release from primary sensory neurons of the lower urinary tract. Eur Urol [doi:10.1016/ j.eururo.2007.01.016]
20. Birder LA and de Groat WC (2007) Mechanisms of disease: Involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol 4 46-54
21. Ishihama H et al. (2006) Activation of alpha1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J Urol 175: 358-364
22. Furuya S et al. (1982) Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 128: 836-839
23. Appell RA et al. (1980) The effects of epidural anesthesia on the urethral closure pressure profile in patients with prostatic enlargement. J Urol 124: 410-411
24. Andersson KE (2002) Alpha-adrenoceptors and benign prostatic hyperplasia: Basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 19: 390-396
25. Brading AF et al. (1999) α1-Adrenoceptors in urethral function. Eur Urol 36 (Suppl 1): 74-79
26. Nasu K et al. (1998) Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human proximal urethra. Br J Pharmacol 123: 1289-1293
27. Taki N et al. (1999) Evidence for predominant mediation of alpha1-adrenoceptor in the tonus of entire urethra of women. J Urol 162: 1829-1832
28. Daniels DV et al. (1999) Human cloned alpha1A-adrenoceptor isoforms display alpha1L-adrenoceptor pharmacology in functional studies. Eur J Pharmacol 370: 337-343
29. Fukasawa R et al. (1998) The alpha1L-adrenoceptor subtype in the lower urinary tract: A comparison of human urethra and prostate. Br J Urol 82: 733-737
30. Lepor H and Theune C (1995) Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. J Urol 154: 116-118
31. Nasu K et al. (1996) Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: Comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 119: 797-803
32. Kurimoto S et al. (1995) Quantitative autoradiography of alpha 1 adrenoceptors with [3H]tamsulosin in human hypertrophied prostate using computerized image analysis. Histochem J 27: 1007-1013
33. Walden PD et al. (1999) Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 161: 635-640
34. Lepor H et al. (1993) Binding and functional properties of alpha1 adrenoceptors in different regions of the human prostate. J Urol 150: 253-256
35. Moriyama N et al. (1994) Multidirectional contraction of human hypertrophied prostate. Gen Pharmacol 25: 1459-1464
36. Morishima S et al. (2007) Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding. J Urol 177: 377-381
37. Djavan B and Marberger M (1999) A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1-13
38. Chon JK et al. (1999) Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 161: 2002-2008
39. Tahmatzopoulos A and Kyprianou N (2004) Apoptotic impact of alpha1-blockers on prostate cancer growth: A myth or an inviting reality? Prostate 59: 91-100
40. Ilio KY et al. (2001) Apoptotic activity at doxazosin on prostate stroma in vitro is mediated through an autocrine expression of TGF-beta1. Prostate 48: 131-135
41. Garrison JB and Kyprianou N (2006) Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res 66: 464-472
42. McConnell JD et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387-2398
43. Roehrborn CG (2006) Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 9: 121-125
44. Smith P et al. (1999) Influence of the alpha1-adrenergic antagonist, doxazosin, on noradrenaline-induced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells. Prostate 38: 216-227
45. Boesch ST et al. (1999) Modulation of the differentiation status of cultured prostatic smooth muscle cells by an alpha1-adrenergic receptor antagonist. Prostate 39: 226-233
46. Brannigan RE (2004) Ejaculatory disorders and lower urinary tract symptoms. Curr Urol Rep 5: 280-286
47. Carbone DJ Jr and Hodges S (2003) Medical therapy for benign prostatic hyperplasia: Sexual dysfunction and impact on quality of life. Int J Impot Res 15: 299-306
48. Moriyama N et al. (1997) Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human vas deferens: Comparison with those of epididymal and pelvic portions. Br J Pharmacol 122: 1009-1014
49. Furukawa K et al. (1995) Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens. Br J Pharmacol 116: 1605-1610
50. Amobi N et al. (1999) Functional characterization of alpha1-adrenoceptor subtypes in longitudinal and circular muscle of human vas deferens. Eur J Pharmacol 367: 291-298
51. Tambaro S et al. (2005) Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: Relevance to ejaculation delays. J Pharmacol Exp Ther 312: 710-717
52. Giuliano F et al. (2004) A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats. BJU Int 93: 605-608
53. Giuliano FA et al. (2006) Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats. BJU Int 98: 876-879
54. Domyancic AV and Morilak DA (1997) Distribution of alpha1A adrenergic receptor mRNA in the rat brain visualized by in situ hybridization. J Comp Neurol 386: 358-378
55. Day HE et al. (1997) Distribution of alpha 1a-, alpha 1b- and alpha 1d-adrenergic receptor mRNA in the rat brain and spinal cord. J Chem Neuroanat 13: 115-139
56. Thor KB and Donatucci C (2004) Central nervous system control of the lower urinary tract: New pharmacological approaches to stress urinary incontinence in women. J Urol 172: 27-33
57. Ishizuka O et al. (1996) Micturition in conscious rats with and without bladder outlet obstruction: Role of spinal alpha 1-adrenoceptors. Br J Pharmacol 117: 962-966
58. Persson K et al. (1998) Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 275: R1366-R1373
59. Yoshiyama M et al. (2000) Role of spinal alpha(1)-adrenergic mechanisms in the control of lower urinary tract in the rat. Brain Res 882: 36-44
60. Yoshiyama M and De Groat WC (2001) Role of spinal alpha1-adrenoceptor subtypes in the bladder reflex in anesthetized rats. Am J Physiol Regul Integr Comp Physiol 280: R1414-R1419
61. Sugaya K et al. (2002) Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci Lett 328: 74-76
62. Yokoyama O et al. (2006) Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats. Neurourol Urodyn 25: 461-467
63. Chan Q et al. (2005) Function of the lower urinary tract in mice lacking alpha1d-adrenoceptor. J Urol 174: 370-374
64. Mitsui T et al. (2005) Transplantation of neuronal and glial restricted precursors into contused spinal cord - improves bladder and motor functions, decreases thermal hypersensitivity, and modifies intraspinal circuitry. J Neurosci 25: 9624-9636
65. Blue D et a. (2002) RO700004, a selective α1A-adrenoceptor antagonist, does not improve lower urinary tract symptoms in men with benign prostatic hyperplasia [abstract]. J Urol 167 (Suppl): 265
66. Ikemoto I et al. (2003) Usefulness of tamsulosin hydrochloride and naftopidil In patients with urinary disturbances caused by benign prostatic hyperplasia: A comparative, randomized, two-drug crossover study. Int J Urol 10: 587-594
67. Gotoh M et al. (2005) Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: A randomized controlled trial. BJU Int 96: 581-586
68. Nishino Y et al. (2006) Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: A randomized crossover study. BJU Int 97: 747-751
69. Kawabe K et al. (2006) Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98: 1019-1024
70. Barendrecht MM et al. (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: The cardiovascular system. BJU Int 95 (Suppl 4): 19-28
71. ALLHAT Collaborative Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283: 1967-1975
72. Stafford RS et al. (2004) Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA 291: 54-62
73. Hartung R et al. (2006) Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. J Urol 175: 624-628
74. Ethilali M et al. (2006) Long-term efficacy and safety of alfuzosin 10 mg once daily: A 2-year experience in 'real-life' practice. BJU Int 97: 513-519
75. Michel MC and Chapple CR (2006) Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). Eur Urol 49: 501-508
76. Auerbach SM et al. (2004) Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 64: 998-1003
77. Giuliano F et al. (2006) Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 67: 1199-1204
78. Chung BH and Hong SJ (2006) Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension. BJU Int 97: 90-95
79. Kirby RS (1995) Doxazosin in benign prostatic hyperplasia: Effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 46: 182-186
80. Lowe FC (1994) Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: A combined analysis. Urology 44: 46-51
81. Kaplan SA and D'Alisera PM (1998) Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: A pooled analysis of seven double-blind, placebo-controlled studies. J Gerontol A Biol Sci Med Sci 53: M201-M206
82. Os I and Stokke HP (1999) Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group. J Cardiovasc Pharmacol 33: 791-797
83. Buzelin JM et al. (1997) Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol 80 597-605
84. Lepor H et al. (2000) The mechanism of adverse events associated with terazosin: An analysis of the Veterans Affairs cooperative study. J Urol 163: 1134-1137
85. De Mey C (2000) Alpha1-blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: What are the relevant differences in randomised controlled trials? Eur Urol 38 (Suppl 1): 25-39
86. Os I (2006) Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure. Int J Clin Pharmacol Ther 44 99-106
87. Mottet N et al. (2003) Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur Urol 44: 101-105
88. Becker AJ et al. (1998) Oral phentolamine as treatment for erectile dysfunction. J Urol 159: 1214-1216
89. Schulman C (2001) Impact of treatment of BPH on sexuality. Prostate Cancer Prostatic Dis 4: S12-S16
90. Hellstrom WJ and Sikka SC (2006) Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 176: 1529-1533
91. Hisasue S et al. (2006) Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol 13: 1311-1316
92. van Dijk MM et al. (2006) Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 66: 287-301
93. Speakman M (2006) Efficacy and safety of tamsulosin OCAS. BJU Int 98 (Suppl 2): 13-17
94. Goktas S et al. (2006) Recovery of abnormal ejaculation by intermittent tamsulosin treatment. J Urol 175: 650-652
95. Chang DF and Campbell JR (2005) Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 31: 664-673
96. Oshika T et al. (2007) Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist. Am J Ophthalmol 148: 150-151
97. Lawrentschuk N and Bylsma GW (2006) Intraoperative 'floppy iris' syndrome and its relationship to tamsulosin: A urologist's guide. BJU Int 97: 2-4
98. Schwinn DA and Afshari NA (2006) alpha(1)-Adrenergic receptor antagonists and the iris: Now mechanistic insights into floppy iris syndrome. Surv Ophthalmol 51: 501-512